Lead with liquid
Lead with Guardant360® CDx
Guideline-complete genomic profiling results
The first FDA-approved comprehensive liquid biopsy
Receive comprehensive genomic results in just 7 days
Guide appropriate treatment for more newly diagnosed NSCLC patients.*
In the NILE study, a prospective, head-to-head study of 282 patients, leading with Guardant360 LDT detected 20% more patients with biomarkers than leading with tissue testing.19
*Disclaimer: This content has not been reviewed by the FDA. Data shown for the performance of Guardant360® Laboratory Developed Test (LDT) does not convey the performance of Guardant360 CDx.
*Disclaimer: This content has not been reviewed by the FDA. Data shown for the performance of Guardant360® Laboratory Developed Test (LDT) does not convey the performance of Guardant360 CDx.
Inform treatment decisions across all solid tumors
Guardant360 CDx Gene List
You might also be interested in:
Enhance Your Practice with Guardant360 CDx
Make Guardant360 CDx a routine part of care
A New Standard of Care
Rebecca Nagy, Vice President of Medical Affairs, discusses how complete genomic profiling has become a standard of care
The Importance of FDA Approval when Choosing Liquid Biopsy
The latest webinar from our Peer Education Program